RTI Health Solutions, Sheffield, UK.
Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):111-23. doi: 10.1586/14737167.2015.965152. Epub 2015 Jan 2.
A systematic review identified studies eliciting utility decrements from myocardial infarction (MI) and stroke in patients with Type 2 diabetes mellitus (T2DM) and examined their use in economic models of new diabetes treatments. In 16 utility studies in patients with T2DM, utility decrements in the first year ranged from 0.017 to 0.226 for MI and from 0.034 to 0.590 for stroke. Sixteen of 19 economic evaluations of new treatments for T2DM included utility decrements for an MI and/or stroke from one of the 16 utility studies. Decrements for MI ranged from 0.012 to 0.180 in the first year. Decrements for stroke ranged from 0.044 to 0.690 in the first year. Utility studies in patients with T2DM provide little information about changes in utility decrements by time since the event and by disease severity. Cost-effectiveness studies do not always indicate how these values were used in the analysis.
一项系统评价从患有 2 型糖尿病（T2DM）的患者中确定了与心肌梗死（MI）和中风相关的效用降低研究，并研究了它们在新的糖尿病治疗经济学模型中的应用。在 16 项 T2DM 患者的效用研究中，MI 第一年的效用降低幅度从 0.017 到 0.226，中风从 0.034 到 0.590。19 项新的 T2DM 治疗经济评估中有 16 项包括了从 16 项效用研究中的一项中得出的 MI 和/或中风的效用降低。第一年 MI 的降低幅度为 0.012 至 0.180。第一年中风的降低幅度为 0.044 至 0.690。T2DM 患者的效用研究很少提供关于事件发生后时间和疾病严重程度的效用降低变化的信息。成本效益研究并不总是表明这些值在分析中是如何使用的。
